CytomX Therapeutics, Inc. (NASDAQ:CTMX) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, July 24th.
Other equities research analysts have also recently issued research reports about the company. HC Wainwright initiated coverage on CytomX Therapeutics in a report on Monday, March 27th. They set a “buy” rating and a $24.00 price objective on the stock. Cowen and Company reaffirmed a “buy” rating on shares of CytomX Therapeutics in a research report on Wednesday, June 28th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $25.00 target price on shares of CytomX Therapeutics in a research report on Tuesday, June 6th. Zacks Investment Research raised CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a research report on Wednesday, May 3rd. Finally, Cann reaffirmed a “hold” rating on shares of CytomX Therapeutics in a research report on Thursday, March 30th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $25.60.
Shares of CytomX Therapeutics (NASDAQ CTMX) opened at 13.98 on Monday. The firm has a 50-day moving average price of $14.70 and a 200-day moving average price of $14.50. CytomX Therapeutics has a 52-week low of $9.85 and a 52-week high of $20.02. The stock’s market cap is $515.40 million.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.30. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. The business had revenue of $8.75 million for the quarter, compared to analyst estimates of $4.95 million. On average, analysts anticipate that CytomX Therapeutics will post ($1.47) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “CytomX Therapeutics, Inc. (CTMX) Cut to Sell at BidaskClub” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://transcriptdaily.com/2017/08/13/cytomx-therapeutics-inc-ctmx-cut-to-sell-at-bidaskclub-updated-updated.html.
In other news, Director Frederick W. Gluck sold 5,000 shares of CytomX Therapeutics stock in a transaction dated Monday, June 26th. The stock was sold at an average price of $14.61, for a total transaction of $73,050.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Robert I. Tepper sold 15,000 shares of CytomX Therapeutics stock in a transaction dated Thursday, June 29th. The stock was sold at an average price of $16.00, for a total value of $240,000.00. Following the sale, the insider now directly owns 44,777 shares in the company, valued at $716,432. The disclosure for this sale can be found here. Insiders sold 39,343 shares of company stock worth $606,856 over the last three months. 4.70% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of CTMX. Russell Investments Group Ltd. increased its position in CytomX Therapeutics by 1.3% in the second quarter. Russell Investments Group Ltd. now owns 22,134 shares of the biotechnology company’s stock worth $343,000 after buying an additional 292 shares during the period. American International Group Inc. increased its position in CytomX Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,580 shares of the biotechnology company’s stock worth $217,000 after buying an additional 834 shares during the period. Legal & General Group Plc increased its position in CytomX Therapeutics by 28.6% in the second quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after buying an additional 1,434 shares during the period. Teachers Advisors LLC increased its position in CytomX Therapeutics by 6.7% in the fourth quarter. Teachers Advisors LLC now owns 34,961 shares of the biotechnology company’s stock worth $384,000 after buying an additional 2,209 shares during the period. Finally, Swiss National Bank increased its position in CytomX Therapeutics by 19.1% in the first quarter. Swiss National Bank now owns 26,800 shares of the biotechnology company’s stock worth $463,000 after buying an additional 4,300 shares during the period. Institutional investors and hedge funds own 52.33% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.